| 1. |
- List, Thomas, et al.
(författare)
-
Immunocytokines : a review of molecules in clinical development for cancer
- 2013
-
Ingår i: Clinical Pharmacology. - : Nakladatelstvi Lidove noviny. - 1179-1438. ; 5, s. 29-45
-
Tidskriftsartikel (refereegranskat)abstract
- The concept of therapeutically enhancing the immune system's responsiveness to tumors is long standing. Several cytokines have been investigated in clinical trials for their therapeutic activity in cancer patients. However, substantial side effects and unfavorable pharmacokinetic properties have been a major drawback hampering the administration of therapeutically relevant doses. The use of recombinant antibody-cytokine fusion proteins promises to significantly enhance the therapeutic index of cytokines by targeting them to the site of disease. This review aims to provide a concise and complete overview of the preclinical data and clinical results currently available for all immunocytokines having reached clinical development.
|
|
| 2. |
|
|
| 3. |
- Valdimarsson, Valentinus T., et al.
(författare)
-
Repeat procedures for recurrent colorectal liver metastases : Analysis of long-term liver regeneration and outcome
- 2019
-
Ingår i: Cancer Management and Research. - 1179-1322. ; 11, s. 2617-2622
-
Tidskriftsartikel (refereegranskat)abstract
- Background and aim: Repeat hepatectomy is increasingly performed for the management of recurrent colorectal liver metastases (CRLM). The aim of this study was to evaluate longterm functional liver volume (FLV) after a second hepatic procedure and to measure survival outcome. Methods: In this retrospective cohort study, patients treated for recurrent CRLM in the years 2005-2015 at two liver centers were included. Total FLV was calculated before the first procedure and before and after the second procedure. Overall survival was calculated. Results: Eighty-two patients were identified. The median follow-up was 53 (40-71) months from the first procedure. The median interval between first and second procedure was 13 (8-22) months. The initial FLV was 1584 (1313-1927) mL. The FLV was 1438 (1204-1896) mL after the first procedure and 1470 (1172-1699) mL after the second procedure (P<0.001). After the second procedure, a total of ten patients (12%) had a residual liver volume of less than 75% of the initial liver volume. The 5-year overall survival was 37 (26-54)% after the second procedure. Conclusion: Small changes in FLV were found after two hepatic procedures but with considerable inter-individual variation. Patients selected for a repeated hepatic procedure for recurrent CRLM had an acceptable survival.
|
|
